Actively Recruiting
Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)
Led by National Healthcare Group Polyclinics · Updated on 2026-03-20
240
Participants Needed
1
Research Sites
212 weeks
Total Duration
On this page
Sponsors
N
National Healthcare Group Polyclinics
Lead Sponsor
N
National Medical Research Council (NMRC), Singapore
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting. The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting. Researchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management
CONDITIONS
Official Title
Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Singaporeans or Singapore Permanent Residents
- Aged 21 to 65 years old
- Physician diagnosed asthma for at least 4 weeks
- On or will start Global Initiative for Asthma (GINA) 2025 step 1-3 treatment
- No asthma exacerbations in the 4 weeks before randomisation
- Able and willing to attend study appointments approximately every 4 months for 1 year
- Able to provide informed consent
- Stable cardiovascular status with controlled hypertension and no active heart disease or arrhythmias
You will not qualify if you...
- History of life-threatening asthma requiring intubation or intensive care
- Severe or difficult to treat asthma
- Current use of long-term immunosuppression, Montelukast, Theophylline, or long-term oral steroids
- Other known causes of eosinophilia besides asthma
- Current use of beta-blockers including eye drops
- Use of glucocorticoids (oral, rectal, parenteral) within 30 days or depot glucocorticoids within 12 weeks before recruitment
- Diagnosed with Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, or bronchiectasis
- Significant diseases or disorders that may risk safety or affect study participation
- Currently enrolled in another interventional asthma trial
- Pregnant or planning pregnancy during the study
- Planned travel outside the country for 16 or more consecutive weeks during the study
- Assessed as unable to follow study instructions or procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Healthcare Group Polyclinics
Singapore, Singapore, 308205
Actively Recruiting
Research Team
W
Wern Ee Tang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here